CD86 and adenoma: Tumors with Ki67 elevated to ≥3%, levels correlated with an increased risk of recurrence, had significantly elevated PD-L1 and, although we found no differences in immune checkpoint molecules among the functioning adenomas compared to non-functioning adenomas at large, a small subset of 4 ACTH-secreting tumors had significantly elevated CD80 and CD86.